Diamante SB srl
June 22, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Immunology
Diamante is a female-led biotechnology company pioneering plant derived, immune tolerance-inducing therapies for autoimmune diseases. Its proprietary platform is designed to reset the immune system without immunosuppression, enabling truly disease modifying treatments and multiple partnership opportunities across indications. The lead program targets Rheumatoid Arthritis, a global market expected to reach ~$52B by 2033. Current therapies largely manage symptoms and cause severe side effects in up to 20% of patients. Diamante's candidate has shown strong preclinical efficacy, with EU IMPD submission planned for late 2026 and Phase 1 trials in 2027. The company has secured $8.0M in committed public equity funding and is opening a $1-3M lead investor slot to complete the round. With an in house GMP facility targeting AIFA certification in Q1 2027, Diamante is vertically integrated for efficient scale up and manufacturing control.
Company HQ City:
Verona
Company HQ State:
Italy
Company HQ Country:
Italy
Year Founded:
2016
CEO
Valentina
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}